mRNA |
dabrafenib |
CTRPv2 |
pan-cancer |
AAC |
0.022 |
0.7 |
mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.015 |
0.7 |
mRNA |
CD-1530 |
CTRPv2 |
pan-cancer |
AAC |
0.017 |
0.7 |
mRNA |
HG-5-88-01 |
GDSC1000 |
pan-cancer |
AAC |
-0.021 |
0.7 |
mRNA |
MS-275 |
GDSC1000 |
pan-cancer |
AAC |
-0.026 |
0.7 |
mRNA |
MPS-1-IN-1 |
GDSC1000 |
pan-cancer |
AAC |
0.015 |
0.7 |
mRNA |
JQ-1:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.015 |
0.7 |
mRNA |
Compound 23 citrate |
CTRPv2 |
pan-cancer |
AAC |
-0.014 |
0.7 |
mRNA |
Bosutinib |
FIMM |
pan-cancer |
AAC |
0.2 |
0.7 |
mRNA |
thapsigargin |
gCSI |
pan-cancer |
AAC |
0.024 |
0.7 |